Researchers validate preclinical effectiveness of TB drug target

November 29, 2011 in Diseases, Conditions, Syndromes

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin, there currently is no antibiotic on the market that targets gyrase B. In laboratory experiments, SRI researchers found that by targeting gyrase B, are killed whether they are replicating or dormant. Further studies will be conducted toward the development of a TB drug against gyrase B.

"One of the greatest needs in infectious disease treatment is a drug that allows a shorter length of treatment," said Peter Madrid, Ph.D., program director in the Center for Infectious Disease and Biodefense Research, SRI Biosciences Division. "Though our program is still in the preclinical phase of research, with a number of years of required testing ahead, our goal is to develop a drug that will improve the treatment process for TB patients."

currently undergo treatment for six months and take a combination of at least four different drugs. There are often challenges to treatment effectiveness because of the long treatment time, including low patient treatment compliance and high rates of . Tuberculosis that is resistant to multiple drugs takes even longer to treat, usually 18 to 24 months.

Provided by SRI International

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Mysterious illness kills two in southeast Alabama

(AP)—Alabama health officials say a mysterious respiratory illness has left five people hospitalized and two dead in the southeastern part of the state.

Diseases, Conditions, Syndromes created 41 minutes ago | popularity not rated yet | comments 0

Researchers find genetic risk factor for pulmonary fibrosis

A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibros ...

Diseases, Conditions, Syndromes created 14 hours ago | popularity not rated yet | comments 0

Biomarkers discovered for inflammatory bowel disease

Using the Department of Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers have identified a number of biomarkers for inflammatory bowel disease (IBD), which could help with earlier diagnosis and ...

Diseases, Conditions, Syndromes created 14 hours ago | popularity 5 / 5 (1) | comments 0

CDC says high number of public pools contain microbes

(HealthDay)—Three-quarters of public schools in the metro Atlanta area contain microbes, including bacteria indicating the presence of fecal matter, according to research published in the May 17 issue of ...

Diseases, Conditions, Syndromes created 15 hours ago | popularity not rated yet | comments 0

Study examines outbreak of spinal infections in Michigan

(HealthDay)—Factors such as increased case finding may explain why Michigan had half of the total spinal infections associated with contaminated methylprednisolone acetate in the recent fungal meningitis ...

Diseases, Conditions, Syndromes created 15 hours ago | popularity not rated yet | comments 0


Italy approves law on controversial stem cell therapy

Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill ...

Beta-blockers may boost chemo effect in childhood cancer

Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Jo ...

Japan hospital tests powerful breast cancer therapy

A Japanese cancer specialist said Wednesday she has started the world's first clinical trial of a powerful, non-surgical, short-term radiation therapy for breast cancer.

Portland, Ore., rejecting water fluoridation

(AP)—The mayor of Portland, Ore., has conceded defeat in an effort to add fluoride to the city's drinking water.

Targeting the X-factor to tackle cardiovascular disease

New research at The University of Nottingham aimed at preventing harmful blood clots associated with heart disease and stroke has recently received a major funding boost from the British Heart Foundation.

Study focuses on new mums' sleepiness and injury risk on the road

New mothers throughout Australia are needed to help QUT sleep researchers investigate whether the disrupted sleep experienced by mothers when caring for their new baby raises the risk of injury while driving.